tetano
Editor, Senior Moderator
Immun Ageing
. 2022 Aug 23;19(1):39.
doi: 10.1186/s12979-022-00296-7.
Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons
Chris P Verschoor[SUP] 1 2 [/SUP], Daniel W Belsky[SUP] 3 4 [/SUP], Melissa K Andrew[SUP] 5 [/SUP], Laura Haynes[SUP] 6 [/SUP], Mark Loeb[SUP] 7 [/SUP], Graham Pawelec[SUP] 8 9 [/SUP], Janet E McElhaney[SUP] 8 [/SUP], George A Kuchel[SUP] 6 [/SUP]
Affiliations
Abstract
Background: Biological aging represents a loss of integrity and functionality of physiological systems over time. While associated with an enhanced risk of adverse outcomes such as hospitalization, disability and death following infection, its role in perceived age-related declines in vaccine responses has yet to be fully elucidated. Using data and biosamples from a 4-year clinical trial comparing immune responses of standard- and high-dose influenza vaccination, we quantified biological age (BA) prior to vaccination in adults over 65 years old (n = 292) using a panel of ten serological biomarkers (albumin, alanine aminotransferase, creatinine, ferritin, free thyroxine, cholesterol, high-density lipoprotein, triglycerides, tumour necrosis factor, interleukin-6) as implemented in the BioAge R package. Hemagglutination inhibition antibody titres against influenza A/H1N1, A/H3N2 and B were quantified prior to vaccination and 4-, 10- and 20- weeks post-vaccination.
Results: Counter to our hypothesis, advanced BA was associated with improved post-vaccination antibody titres against the different viral types and subtypes. However, this was dependent on both vaccine dose and CMV serostatus, as associations were only apparent for high-dose recipients (d = 0.16-0.26), and were largely diminished for CMV positive high-dose recipients.
Conclusions: These findings emphasize two important points: first, the loss of physiological integrity related to biological aging may not be a ubiquitous driver of immune decline in older adults; and second, latent factors such as CMV infection (prevalent in up to 90% of older adults worldwide) may contribute to the heterogeneity in vaccine responses of older adults more than previously thought.
Keywords: Biological age; Canadian longitudinal study on aging; Cytomegalovirus; Influenza; Older adults; Vaccination.
. 2022 Aug 23;19(1):39.
doi: 10.1186/s12979-022-00296-7.
Advanced biological age is associated with improved antibody responses in older high-dose influenza vaccine recipients over four consecutive seasons
Chris P Verschoor[SUP] 1 2 [/SUP], Daniel W Belsky[SUP] 3 4 [/SUP], Melissa K Andrew[SUP] 5 [/SUP], Laura Haynes[SUP] 6 [/SUP], Mark Loeb[SUP] 7 [/SUP], Graham Pawelec[SUP] 8 9 [/SUP], Janet E McElhaney[SUP] 8 [/SUP], George A Kuchel[SUP] 6 [/SUP]
Affiliations
- PMID: 35999604
- DOI: 10.1186/s12979-022-00296-7
Abstract
Background: Biological aging represents a loss of integrity and functionality of physiological systems over time. While associated with an enhanced risk of adverse outcomes such as hospitalization, disability and death following infection, its role in perceived age-related declines in vaccine responses has yet to be fully elucidated. Using data and biosamples from a 4-year clinical trial comparing immune responses of standard- and high-dose influenza vaccination, we quantified biological age (BA) prior to vaccination in adults over 65 years old (n = 292) using a panel of ten serological biomarkers (albumin, alanine aminotransferase, creatinine, ferritin, free thyroxine, cholesterol, high-density lipoprotein, triglycerides, tumour necrosis factor, interleukin-6) as implemented in the BioAge R package. Hemagglutination inhibition antibody titres against influenza A/H1N1, A/H3N2 and B were quantified prior to vaccination and 4-, 10- and 20- weeks post-vaccination.
Results: Counter to our hypothesis, advanced BA was associated with improved post-vaccination antibody titres against the different viral types and subtypes. However, this was dependent on both vaccine dose and CMV serostatus, as associations were only apparent for high-dose recipients (d = 0.16-0.26), and were largely diminished for CMV positive high-dose recipients.
Conclusions: These findings emphasize two important points: first, the loss of physiological integrity related to biological aging may not be a ubiquitous driver of immune decline in older adults; and second, latent factors such as CMV infection (prevalent in up to 90% of older adults worldwide) may contribute to the heterogeneity in vaccine responses of older adults more than previously thought.
Keywords: Biological age; Canadian longitudinal study on aging; Cytomegalovirus; Influenza; Older adults; Vaccination.